Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.56 |
| ▸ | CMA1 | P23946 | 6/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287127 | 0.92 | REN (0.51) | RENCMA1AGTR1AGTR2LNPEP | |
| SCHEMBL18699907 | 0.92 | REN (0.52) | RENCMA1AGTR1AGTR2LNPEP | |
| SCHEMBL29566322 | 0.85 | CMA1 (0.53) | RENCMA1 | |
| SCHEMBL17274225 | 0.84 | REN (0.47) | RENAGTR1AGTR2LNPEPANPEP | |
| Angiotensin Iv SCHEMBL4322236 | 0.83 | LNPEP (0.68) | RENAGTR1AGTR2LNPEPANPEP | |
| Angiotensin Iv SCHEMBL4322224 | 0.83 | LNPEP (0.68) | RENAGTR1AGTR2LNPEPANPEP | |
| SCHEMBL11204440 | 0.83 | LNPEP (0.60) | AGTR1AGTR2LNPEPANPEP | |
| SCHEMBL11204436 | 0.83 | LNPEP (0.60) | AGTR1AGTR2LNPEPANPEP | |
| SCHEMBL17274191 | 0.83 | LNPEP (0.53) | AGTR1AGTR2LNPEPANPEP | |
| SCHEMBL19780600 | 0.83 | C5AR1 (0.52) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | REN 666/4885CMA1 3510/4885AGTR1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.